On October 11, 2023 C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, reported plans to share data from the Phase 1 dose escalation portions of the ongoing Phase 1/2 trials of CFT7455 and CFT8634 (Press release, C4 Therapeutics, OCT 11, 2023, View Source [SID1234635849]). The CFT8634 Phase 1 dose escalation data has been accepted as a poster presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place from November 1 – 4, 2023 in Dublin, Ireland. C4T will host a company-sponsored event on December 12, 2023, to share the CFT7455 dose escalation data in relapsed/refractory multiple myeloma (R/R MM).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Upcoming CFT8634 Clinical Data
The Phase 1/2 trial is designed to characterize safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and evidence of anti-tumor activity of CFT8634 based on RECIST 1.1 criteria. As of August 29, 2023, 32 patients were enrolled across six dose escalation cohorts using a daily dosing schedule.
CTOS Presentation Details
Title: Initial results from a Phase 1 study of CFT8634, a novel bifunctional degradation activating compound (BiDAC) degrader of BRD9, in synovial sarcoma and SMARCB1-null tumors
Format: Poster Presentation
Time: Thursday, November 2, 2023; 5:30 PM – 6:30 PM IST (9:00 AM EST)
Presenter: Mark Agulnik, M.D., sarcoma section chief, department of medical oncology and therapeutics research, City of Hope
Data included in the poster presentation will be PK, PD, safety and RECIST criteria efficacy measures.
Upcoming CFT7455 Clinical Data
The Phase 1/2 trial is designed to characterize the safety, tolerability, PK, PD and anti-tumor activity of CFT7455 in patients with R/R MM or relapsed/refractory non-Hodgkin’s lymphoma (R/R NHL). The Phase 1 dose escalation portion of the ongoing Phase 1/2 trial has utilized a 14 days on/14 days off dosing schedule within which both daily dosing and Monday/Wednesday/Friday dosing were explored. C4T has completed the Phase 1 dose escalation for CFT7455 as a monotherapy in R/R MM using a 14 days on/14 days off dosing schedule; 22 patients were enrolled across five dose escalation cohorts for this portion of the study. Enrollment continues for the Phase 1 dose escalation evaluating CFT7455 with dexamethasone in R/R MM and as a monotherapy in R/R NHL.
At a company-sponsored event on December 12, 2023, C4T plans to present Phase 1 dose escalation data that focuses on the CFT7455 monotherapy regimen in R/R MM.
Upcoming Investor Conferences
The company is planning to participate in the following upcoming investor conferences:
November 8, 2023: Management will participate in the UBS Biopharma Conference taking place in Miami, FL.
November 14, 2023: Management will participate in the Stifel 2023 Conference taking place in New York, NY.